Atyr Pharma Stock News

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pa

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological path

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pa

Wall Street brokerages predict that aTyr Pharma, Inc. (NASDAQ:LIFE) will post $7.50 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for aTyr Pharmas earnings. The highest sales estimate is $10.00 million and the lowest is $5.00 million. aTyr Pharma reported sales of $2.05 million in the []

Novel engineering approach accelerates generation of new antibody candidates from tRNA synthetase platform. Novel engineering approach accelerates generation of new antibody candidates from tRNA synth

Novel engineering approach accelerates generation of new antibody candidates from tRNA synthetase platform. Novel engineering approach accelerates generation of new antibody candidates from tRNA synth

Analysts forecast that aTyr Pharma, Inc. (NASDAQ:LIFE) will report earnings of ($0.24) per share for the current quarter, according to Zacks. Two analysts have issued estimates for aTyr Pharmas earnings, with estimates ranging from ($0.44) to $0.12. aTyr Pharma reported earnings of ($0.47) per share in the same quarter last year, which indicates a positive []

Equities analysts expect that aTyr Pharma, Inc. (NASDAQ:LIFE) will report earnings per share (EPS) of ($0.24) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for aTyr Pharmas earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at $0.12. aTyr Pharma reported earnings []

Wall Street brokerages expect aTyr Pharma, Inc. (NASDAQ:LIFE) to announce sales of $7.50 million for the current quarter, Zacks reports. Two analysts have provided estimates for aTyr Pharmas earnings, with the lowest sales estimate coming in at $5.00 million and the highest estimate coming in at $10.00 million. aTyr Pharma reported sales of $2.05 million [] The post $7.50 Million in Sales Expected for aTyr Pharma, Inc. (NASDAQ:LIFE) This Quarter appeared first on ETF Daily News .

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, today announced a manufacturing agreement for ATYR1923, aTyr Pharmas lead therapeutic candidate that is currently in clinical development for pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).

aTyr Pharma, Inc. (NASDAQ:LIFE) was the target of a large decline in short interest in October. As of October 29th, there was short interest totalling 793,800 shares, a decline of 34.4% from the October 14th total of 1,210,000 shares. Based on an average daily trading volume, of 5,350,000 shares, the short-interest ratio is presently 0.1 […]

Zacks Investment Research upgraded shares of aTyr Pharma (NASDAQ:LIFE) from a hold rating to a buy rating in a research report released on Tuesday, Zacks.com reports. They currently have $9.75 price target on the biotechnology companys stock. According to Zacks, aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and []